Insulet Corp
NASDAQ:PODD
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
237.06
352.82
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
PODD
stock under the Base Case scenario is
197.27
USD.
Compared to the current market price of 288.73 USD,
Insulet Corp
is
Overvalued by 32%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Insulet Corp.
| US |
|
Abbott Laboratories
NYSE:ABT
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Growing competitive pressure from larger diabetes-technology players, especially Medtronic and Tandem, could slow OmniPod adoption if rival products offer compelling new features or pricing structures.
Insulet’s heavy reliance on the OmniPod franchise increases vulnerability to any manufacturing issues or quality-control setbacks, potentially leading to supply disruptions or product recalls that weigh on brand reputation.
Pressure from insurers and healthcare systems on device reimbursement could squeeze profit margins if Insulet faces downward pricing for its pods, reducing the company’s ability to invest in R&D or marketing.
The rapid uptake of Insulet’s OmniPod system, thanks to tubeless convenience and user-friendly design, positions Insulet as a category leader in an expanding insulin-pump market.
Insulet’s upcoming integrations with continuous glucose monitoring solutions, such as Dexcom and Abbott, could create a superior closed-loop system that appeals to a broader patient base, boosting adoption rates and recurring pod sales.
Recurring revenue from OmniPod’s disposable pods ensures a stable, predictable stream of income, enabling Insulet to reinvest in next-generation pump technologies and global market expansion.
Revenue & Expenses Breakdown
Insulet Corp
Balance Sheet Decomposition
Insulet Corp
| Current Assets | 1.9B |
| Cash & Short-Term Investments | 627.2m |
| Receivables | 462.2m |
| Other Current Assets | 770m |
| Non-Current Assets | 1.2B |
| PP&E | 724.1m |
| Intangibles | 156.6m |
| Other Non-Current Assets | 289.2m |
| Current Liabilities | 647.7m |
| Accounts Payable | 48.2m |
| Accrued Liabilities | 519.6m |
| Other Current Liabilities | 79.9m |
| Non-Current Liabilities | 997.5m |
| Long-Term Debt | 934.9m |
| Other Non-Current Liabilities | 62.6m |
Free Cash Flow Analysis
Insulet Corp
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Insulet Corp
|
Revenue
|
2.5B
USD
|
|
Cost of Revenue
|
-719.7m
USD
|
|
Gross Profit
|
1.8B
USD
|
|
Operating Expenses
|
-1.4B
USD
|
|
Operating Income
|
436.9m
USD
|
|
Other Expenses
|
-190.7m
USD
|
|
Net Income
|
246.2m
USD
|
PODD Profitability Score
Profitability Due Diligence
Insulet Corp's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
Score
Insulet Corp's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
PODD Solvency Score
Solvency Due Diligence
Insulet Corp's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Score
Insulet Corp's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PODD Price Targets Summary
Insulet Corp
According to Wall Street analysts, the average 1-year price target for
PODD
is 385.61 USD
with a low forecast of 319.16 USD and a high forecast of 453.6 USD.
Dividends
Current shareholder yield for
PODD is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
PODD
stock under the Base Case scenario is
197.27
USD.
Compared to the current market price of 288.73 USD,
Insulet Corp
is
Overvalued by 32%.